Evidence map›Paper›PMID 40861445›Full record

ArticleFrontiers in immunology2025

Investigation into the prognostic factors of early recurrence and progression in previously untreated diffuse large B-cell lymphoma and a statistical prediction model for POD12.

Ke Lian, Wenyao Zhu, Zhihui Hu, Fang Su, CaiXia Xu, Hui Wang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ke LianDepartment Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
Wenyao ZhuDepartment of Radiotherapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Zhihui HuDepartment Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
Fang SuDepartment of Cancer Prevention and Control, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
CaiXia XuDepartment of Oncology, Houma People's Hospital, Houma, Shanxi, China.
Hui WangSchool of Data Sciences, Zhejiang University of Finance and Economics, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The objective of this study is to evaluate the incidence, prognostic value, and risk factors of progression of disease within 12 months (POD12) in patients with diffuse large B-cell lymphoma (DLBCL). Methods: A retrospective analysis of the clinical, pathological, and follow-up data was carried out on 69 DLBCL cases in Shanxi Bethune Hospital from January 2016 to June 2020. One-way ANOVA and multivariate Cox regression analysis were used to explore the correlation between POD12 and prognosis, and logistic regression analysis was used to explore the risk factors of POD12, accompanied by prediction models based on convolutional neural networks and long short-term memory (CNN-LSTM), as well as particle swarm optimization and general regression neural network (PSO-GRNN) models. Results: (1) POD12 is significantly correlated with PFS (

Indexed as

Lymphoma, Large B-Cell, DiffuseModels, StatisticalNeoplasm Recurrence, LocalAdultAgedDisease ProgressionFemaleHumansMaleMiddle AgedNeural Networks, ComputerPrognosisRetrospective StudiesRisk FactorsYoung Adultdiffuse large B cell lymphomaearly progressionprediction model of POD12prognosisrisk factor

Identifiers

PMID40861445
PMCPMC12376053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.